Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases (2021 - 2025)

ARS Pharmaceuticals' Current Leases history spans 5 years, with the latest figure at $583000.0 for Q3 2025.

  • For Q3 2025, Current Leases rose 471.57% year-over-year to $583000.0; the TTM value through Sep 2025 reached $583000.0, up 471.57%, while the annual FY2024 figure was $42000.0, 82.28% down from the prior year.
  • Current Leases for Q3 2025 was $583000.0 at ARS Pharmaceuticals, down from $589000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.1 million in Q1 2022 and bottomed at $42000.0 in Q4 2024.
  • The 5-year median for Current Leases is $233000.0 (2023), against an average of $435315.8.
  • The largest annual shift saw Current Leases tumbled 82.28% in 2024 before it surged 471.57% in 2025.
  • A 5-year view of Current Leases shows it stood at $144000.0 in 2021, then surged by 59.72% to $230000.0 in 2022, then increased by 3.04% to $237000.0 in 2023, then crashed by 82.28% to $42000.0 in 2024, then skyrocketed by 1288.1% to $583000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Current Leases are $583000.0 (Q3 2025), $589000.0 (Q2 2025), and $73000.0 (Q1 2025).